Comparative Pharmacology
Head-to-head clinical analysis: ETRAFON A versus LOXAPINE SUCCINATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ETRAFON A versus LOXAPINE SUCCINATE.
ETRAFON-A vs LOXAPINE SUCCINATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ETRAFON-A is a combination of perphenazine (a typical antipsychotic) and amitriptyline (a tricyclic antidepressant). Perphenazine blocks dopamine D2 receptors, while amitriptyline inhibits serotonin and norepinephrine reuptake.
Loxapine is a dibenzoxazepine antipsychotic that exerts its effects primarily through antagonism of dopamine D2 and serotonin 5-HT2A receptors. It also has moderate affinity for histamine H1, alpha-1 adrenergic, and muscarinic acetylcholine receptors.
Etrafon-A (perphenazine 4 mg/amitriptyline 10 mg) is not FDA-approved; typical dosing per manufacturer: 1 tablet 3-4 times daily, up to 4 tablets/day. Route: oral.
Initial: 10 mg twice daily orally; increase to 25-50 mg twice daily over 7-10 days; maximum 250 mg/day. IM: 12.5-50 mg every 4-6 hours.
None Documented
None Documented
Terminal elimination half-life: 18-36 hours (mean 24 h); context: in elderly or hepatic impairment may extend beyond 48 h, requiring dose adjustment.
Terminal elimination half-life: 12–19 hours (mean 16 hours) after oral administration; steady-state reached within 3–5 days.
Renal: 50-60% as unchanged drug and metabolites (primarily glucuronide conjugates); Biliary/Fecal: 30-40%; up to 10% excreted via sweat/saliva.
Renal (approximately 60% as metabolites, <1% unchanged) and fecal (approximately 40% as metabolites).
Category C
Category C
Antipsychotic/Antidepressant Combination
Antipsychotic